Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Infection with Fasciola hepatica Aksoy DY; Kerimoglu U; Oto A; Erguven S; Arslan S; Unal S; Batman F; Bayraktar YClin Microbiol Infect 2005[Nov]; 11 (11): 859-61Fascioliasis, caused by the liver fluke Fasciola hepatica, is an infection that occurs worldwide, although humans are accidental hosts. F. hepatica infection comprises two stages, hepatic and biliary, with different signs and symptoms. Stool examination and ELISA can be used for the initial diagnosis. Radiographic techniques, such as computerised tomography and ultrasonography, as well as magnetic resonance imaging, are used widely for confirmation and follow-up of the disease. Invasive techniques, such as percutaneous cholangiography, endoscopic retrograde cholangiography and liver biopsy, may aid in the diagnosis but are not essential. Triclabendazole is recommended as the first-line agent for the treatment of F. hepatica infection, with bithionol as an alternative.|*Fasciola hepatica/drug effects[MESH]|Animals[MESH]|Antiplatyhelmintic Agents/pharmacology/therapeutic use[MESH]|Benzimidazoles/pharmacology/therapeutic use[MESH]|Biopsy[MESH]|Bithionol/pharmacology/therapeutic use[MESH]|Cholangiography[MESH]|Enzyme-Linked Immunosorbent Assay[MESH]|Fascioliasis/diagnosis/*drug therapy/pathology/physiopathology[MESH]|Feces/parasitology[MESH]|Humans[MESH]|Magnetic Resonance Imaging[MESH]|Tomography, X-Ray Computed[MESH]|Triclabendazole[MESH]|Ultrasonography[MESH] |